American Association for Cancer Research
00085472can092543-sup-sfig_2.pdf (8.73 MB)

Supplementary Figure 2 from A Role for BRCA1 in Uterine Leiomyosarcoma

Download (8.73 MB)
journal contribution
posted on 2023-03-30, 19:24 authored by Deyin Xing, George Scangas, Mai Nitta, Lei He, Xuan Xu, Yevgeniya J.M. Ioffe, Paul-Joseph Aspuria, Cyrus Y. Hedvat, Matthew L. Anderson, Esther Oliva, Beth Y. Karlan, Gayatry Mohapatra, Sandra Orsulic
Supplementary Figure 2 from A Role for BRCA1 in Uterine Leiomyosarcoma



Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy with a low survival rate. Currently, there is no effective treatment for ULMS. Infrequent occurrences of human ULMS hamper the understanding of the initiation and progression of the disease, thereby limiting the ability to develop efficient therapies. To elucidate the roles of the p53 and BRCA1 tumor suppressor genes in gynecologic malignancies, we generated mice in which p53 and/or BRCA1 can be conditionally deleted using anti-Müllerian hormone type II receptor (Amhr2)–driven Cre recombinase. We showed that conditional deletion of p53 in mice results in the development of uterine tumors that resemble human ULMS and that concurrent deletion of p53 and BRCA1 significantly accelerates the progression of these tumors. This finding led to our hypothesis that BRCA1 may play a role in human ULMS development. Consistent with this hypothesis, we showed that the BRCA1 protein is absent in 29% of human ULMS and that BRCA1 promoter methylation is the likely mechanism of BRCA1 downregulation. These data indicate that the loss of BRCA1 function may be an important step in the progression of ULMS. Our findings provide a rationale for investigating therapies that target BRCA1 deficiency in ULMS. [Cancer Res 2009;69(21):8231–5]